StockData
Dermata Therapeutics, Inc. logo

Dermata Therapeutics, Inc. (DRMA) stock

DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$0.62−0.04 (-6.01%)

Close on Nov 13, 2026Market cap $2.50MP/E –Yield –

Dermata Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Dermata Therapeutics's total debt was $0 at Dec 31, 2021. For fiscal 2021 it was $0, down 100.0% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$556.16K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2021Dec 31, 2021$0–
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$0–
Q4 FY2020Dec 31, 2020$556.16K–

More Dermata Therapeutics figures

See a number that looks wrong?